The AAV Vector Challenge With Selecta's Dr. Carsten Brunn
Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
We love to hear from our listeners. Send us a message.
The Business of Biotech kicks off our Cell & Gene Miniseries with Dr. Carsten Brunn, President & CEO at Selecta Biosciences. Guest host Erin Harris, chief editor at cellandgene.com, joins us for a discussion on Selecta's ImmTOR platform and how the company is addressing the immunogenicity of adeno-associated virus (AAV) vectors challenge faced by gene therapy companies.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
We love to hear from our listeners. Send us a message.
buzzsprout.comSelecta Biosciences
selectabio.comcellandgene.com
cellandgene.comBusiness of Biotech
lifescienceleader.comBusiness of Biotech newsletter
www9.lifescienceleader.comhttps://www.linkedin.com/in/bencomer/
linkedin.com